Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Pile of papers on a desk

Launching in the February issue of Nature Reviews Immunology, the Preprint Watch column is designed to provide rapid and open access to early data on both COVID-19 and non-COVID-19 immunology preprints. The first two reviews are: Super(antigen) target for SARS-CoV-2 and Sensing our Z-RNA.

During the COVID-19 pandemic the pace of scientific discovery and the race to find solutions required swift communication of results and fuelled an increase in immunology preprints. Journal club communities around the world seized the opportunity to evaluate and critically analyse a large number of SARS-CoV-2 preprints to provide independent insights to frontline researchers, to the general public, and to help prevent misinformation.

The journal group at Precision Immunology Institute at the Icahn School of Medicine, New York, and the OxImmuno Literature Initiative at the University of Oxford were both producing regular preprint summaries related to the COVID-19 emergency. Towards the end of 2020, the journal club teams from both institutes joined forces to launch the Oxford-Mount Sinai (OxMS) preprint journal club. During a weekly virtual joint ‘journal club’ they discuss selected preprints using their cross-institutional expertise and find the latest advancement in immunology. This new way of assessing and reviewing preprint literature may become a new approach to academic peer reviewing.

The full story is available on the Nuffied Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) website

 

 

 

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.